Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study

J. Rosa, P. Widimský, P. Waldauf, L. Lambert, T. Zelinka, M. Táborský, M. Branny, P. Toušek, O. Petrák, K. Čurila, F. Bednář, R. Holaj, B. Štrauch, J. Václavík, I. Nykl, Z. Krátká, E. Kociánová, O. Jiravský, G. Rappová, T. Indra, J. Widimský,

. 2016 ; 67 (2) : 397-403. [pub] 20151222

Language English Country United States

Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16020076

Grant support
NT14155 MZ0 CEP Register

This randomized, multicenter study compared the relative efficacy of renal denervation (RDN) versus pharmacotherapy alone in patients with true resistant hypertension and assessed the effect of spironolactone addition. We present here the 12-month data. A total of 106 patients with true resistant hypertension were enrolled in this study: 52 patients were randomized to RDN and 54 patients to the spironolactone addition, with baseline systolic blood pressure of 159±17 and 155±17 mm Hg and average number of drugs 5.1 and 5.4, respectively. Twelve-month results are available in 101 patients. The intention-to-treat analysis found a comparable mean 24-hour systolic blood pressure decline of 6.4 mm Hg, P=0.001 in RDN versus 8.2 mm Hg, P=0.002 in the pharmacotherapy group. Per-protocol analysis revealed a significant difference of 24-hour systolic blood pressure decline between complete RDN (6.3 mm Hg, P=0.004) and the subgroup where spironolactone was added, and this continued within the 12 months (15 mm Hg, P= 0.003). Renal artery computed tomography angiograms before and after 1 year post-RDN did not reveal any relevant changes. This study shows that over a period of 12 months, RDN is safe, with no serious side effects and no major changes in the renal arteries. RDN in the settings of true resistant hypertension with confirmed compliance is not superior to intensified pharmacological treatment. Spironolactone addition (if tolerated) seems to be more effective in blood pressure reduction.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020076
003      
CZ-PrNML
005      
20190926093036.0
007      
ta
008      
160722s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/HYPERTENSIONAHA.115.06526 $2 doi
024    7_
$a 10.1161/HYPERTENSIONAHA.115.06526 $2 doi
035    __
$a (PubMed)26693818
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rosa, Ján $u 3rd Department of Medicine, Center for Hypertension, General University Hospital and First Faculty of Medicine, Cardiocentre, University Hospital Královské Vinohrady and Third Faculty of Medicine , Charles University, Prague, Czech Republic $7 xx0229097
245    10
$a Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study / $c J. Rosa, P. Widimský, P. Waldauf, L. Lambert, T. Zelinka, M. Táborský, M. Branny, P. Toušek, O. Petrák, K. Čurila, F. Bednář, R. Holaj, B. Štrauch, J. Václavík, I. Nykl, Z. Krátká, E. Kociánová, O. Jiravský, G. Rappová, T. Indra, J. Widimský,
520    9_
$a This randomized, multicenter study compared the relative efficacy of renal denervation (RDN) versus pharmacotherapy alone in patients with true resistant hypertension and assessed the effect of spironolactone addition. We present here the 12-month data. A total of 106 patients with true resistant hypertension were enrolled in this study: 52 patients were randomized to RDN and 54 patients to the spironolactone addition, with baseline systolic blood pressure of 159±17 and 155±17 mm Hg and average number of drugs 5.1 and 5.4, respectively. Twelve-month results are available in 101 patients. The intention-to-treat analysis found a comparable mean 24-hour systolic blood pressure decline of 6.4 mm Hg, P=0.001 in RDN versus 8.2 mm Hg, P=0.002 in the pharmacotherapy group. Per-protocol analysis revealed a significant difference of 24-hour systolic blood pressure decline between complete RDN (6.3 mm Hg, P=0.004) and the subgroup where spironolactone was added, and this continued within the 12 months (15 mm Hg, P= 0.003). Renal artery computed tomography angiograms before and after 1 year post-RDN did not reveal any relevant changes. This study shows that over a period of 12 months, RDN is safe, with no serious side effects and no major changes in the renal arteries. RDN in the settings of true resistant hypertension with confirmed compliance is not superior to intensified pharmacological treatment. Spironolactone addition (if tolerated) seems to be more effective in blood pressure reduction.
650    _2
$a angiografie $7 D000792
650    _2
$a krevní tlak $x fyziologie $7 D001794
650    _2
$a ambulantní monitorování krevního tlaku $7 D018660
650    _2
$a diuretika $x aplikace a dávkování $7 D004232
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a léková rezistence $7 D004351
650    _2
$a echokardiografie $7 D004452
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a hypertenze $x diagnóza $x patofyziologie $x terapie $7 D006973
650    _2
$a ledviny $x inervace $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a spironolakton $x aplikace a dávkování $7 D013148
650    _2
$a sympatektomie $x metody $7 D013562
650    _2
$a časové faktory $7 D013997
650    _2
$a počítačová rentgenová tomografie $7 D014057
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Widimský, Petr, $u Cardiocentre, University Hospital Královské Vinohrady and Third Faculty of Medicine , Charles University, Prague, Czech Republic $d 1954- $7 jn20000402682
700    1_
$a Waldauf, Petr $u Department of Anesthesiology, University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0085547
700    1_
$a Lambert, Lukáš $u Department of Radiology, General University Hospital and First Faculty of Medicine , Charles University, Prague, Czech Republic $7 xx0145830
700    1_
$a Zelinka, Tomáš $u 3rd Department of Medicine, Center for Hypertension, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0074465
700    1_
$a Táborský, Miloš, $u Department of Internal Medicine I, University Hospital Olomouc, Czech Republic, Charles University, Prague, Czech Republic $d 1962- $7 jn20010310074
700    1_
$a Branny, Marian, $u Cardiocentre, Nemocnice Podlesí, Třinec, Czech Republic $d 1962- $7 jo2002139567
700    1_
$a Toušek, Petr $u Cardiocentre, University Hospital Královské Vinohrady and Third Faculty of Medicine , Charles University, Prague, Czech Republic $7 xx0105486
700    1_
$a Petrák, Ondřej $u 3rd Department of Medicine, Center for Hypertension, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0104500
700    1_
$a Čurila, Karol $u Cardiocentre, University Hospital Královské Vinohrady and Third Faculty of Medicine , Charles University, Prague, Czech Republic $7 xx0073736
700    1_
$a Bednář, František $u Cardiocentre, University Hospital Královské Vinohrady and Third Faculty of Medicine , Charles University, Prague, Czech Republic $7 xx0098618
700    1_
$a Holaj, Robert, $u 3rd Department of Medicine, Center for Hypertension, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $d 1965- $7 xx0074140
700    1_
$a Štrauch, Branislav $u 3rd Department of Medicine, Center for Hypertension, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0035015
700    1_
$a Václavík, Jan $u Department of Internal Medicine I, University Hospital Olomouc, Czech Republic $7 xx0169228
700    1_
$a Nykl, Igor $u Cardiocentre, Nemocnice Podlesí, Třinec, Czech Republic $7 xx0118110
700    1_
$a Šomlóová, Z., $u 3rd Department of Medicine, Center for Hypertension, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $d 1983- $7 av2016929974
700    1_
$a Kociánová, Eva $u Department of Internal Medicine I, University Hospital Olomouc, Czech Republic $7 xx0230031
700    1_
$a Jiravský, Otakar $u Cardiocentre, Nemocnice Podlesí, Třinec, Czech Republic $7 xx0098869
700    1_
$a Rappová, Gabriela $u Cardiocentre, Nemocnice Podlesí, Třinec, Czech Republic $7 _AN085600
700    1_
$a Indra, Tomáš $u 3rd Department of Medicine, Center for Hypertension, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0236186
700    1_
$a Widimský, Jiří, $u 3rd Department of Medicine, Center for Hypertension, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $d 1956- $7 jn99240001422
773    0_
$w MED00002089 $t Hypertension $x 1524-4563 $g Roč. 67, č. 2 (2016), s. 397-403
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26693818 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20190926093436 $b ABA008
999    __
$a ok $b bmc $g 1154746 $s 944604
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 67 $c 2 $d 397-403 $e 20151222 $i 1524-4563 $m Hypertension $n Hypertension $x MED00002089
GRA    __
$a NT14155 $p MZ0
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Archiving options